Monday, September 21, 2026RSS
Peptide.Wire

The daily wire on therapeutic peptides. Regulatory, research, compounding and the incretin race, condensed.

Marketstirzepatideeli lillyearningsglp-1

Eli Lilly Q1 report shows GLP-1 franchise still expanding

Commentary on the quarter flags incretin pricing and the Foundayo launch as the next tests for Lilly's growth.

TR
By Tom Reyes · Markets Editor
Apr 30 03:00 ETSource: Moomoo

The wire

  1. 01Eli Lilly's first-quarter results showed continued growth in its GLP-1 business, with pricing pressure and the Foundayo launch cited as upcoming tests.
  2. 02Lilly's incretin volumes and pricing set the commercial backdrop for supply, payer coverage and compounding demand.
  3. 03This is market commentary rather than company disclosure; consult Lilly's own filings for segment figures.

From the source

Eli Lilly Q1 Earnings Review: GLP-1 Leadership Is Still Expanding, but Pricing and Foundayo Are the Next Tests

Read at moomoo.com
Source URL http://www.moomoo.com/community/feed/eli-lilly-q1-earnings-review-glp-1-leadership-is-still-116493732085765